Jonathan Robert Hunt net worth and biography

Jonathan Hunt Biography and Net Worth

A versatile accounting leader with over 25 years of finance and accounting experience across diverse industries, including Fortune 500 companies.

What is Jonathan Robert Hunt's net worth?: The estimated net worth of Jonathan Robert Hunt is at least $141.43 thousand as of November 13th, 2025. Mr. Hunt owns 59,800 shares of Perspective Therapeutics stock worth more than $141,427 as of December 4th. This net worth evaluation does not reflect any other assets that Mr. Hunt may own. Additionally, Mr. Hunt receives a salary of $944,350.00 as CFO at Perspective Therapeutics. Learn More about Jonathan Robert Hunt's net worth.
How old is Jonathan Robert Hunt?: Mr. Hunt is currently 57 years old. There are 2 older executives and no younger executives at Perspective Therapeutics. Learn More on Jonathan Robert Hunt's age.
What is Jonathan Robert Hunt's salary?: As the CFO of Perspective Therapeutics, Inc., Mr. Hunt earns $944,350.00 per year. Learn More on Jonathan Robert Hunt's salary.
How do I contact Jonathan Robert Hunt?: The corporate mailing address for Mr. Hunt and other Perspective Therapeutics executives is 2401 Elliott Avenue, Suite 320, Seattle, WA 98121, United States. Perspective Therapeutics can also be reached via phone at 206-676-0900 and via email at [email protected]. Learn More on Jonathan Robert Hunt's contact information.
Has Jonathan Robert Hunt been buying or selling shares of Perspective Therapeutics?: During the past quarter, Jonathan Robert Hunt has bought $22,330.00 of Perspective Therapeutics stock. Most recently, on Thursday, November 13th, Jonathan Robert Hunt bought 11,000 shares of Perspective Therapeutics stock. The stock was acquired at an average cost of $2.03 per share, with a total value of $22,330.00. Following the completion of the transaction, the chief accounting officer now directly owns 59,800 shares of the company's stock, valued at $121,394. Learn More on Jonathan Robert Hunt's trading history.
Who are Perspective Therapeutics' active insiders?: Perspective Therapeutics' insider roster includes Juan Graham (CFO), Heidi Henson (Director), Jonathan Hunt (CFO), Markus Puhlmann (Chief Medical Officer), Johan Spoor (CEO), Robert Williamson, III (Director), and Lori Woods (Director). Learn More on Perspective Therapeutics' active insiders.
Are insiders buying or selling shares of Perspective Therapeutics?: In the last twelve months, Perspective Therapeutics insiders bought shares 8 times. They purchased a total of 170,169 shares worth more than $428,783.18. The most recent insider tranaction occured on November, 13th when CAO Jonathan Robert Hunt bought 11,000 shares worth more than $22,330.00. Insiders at Perspective Therapeutics own 3.5% of the company. Learn More about insider trades at Perspective Therapeutics.
Information on this page was last updated on 11/13/2025.

Jonathan Robert Hunt Insider Trading History at Perspective Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/13/2025	Buy	11,000	$2.03	$22,330.00	59,800
11/25/2024	Buy	12,829	$3.82	$49,006.78	48,800
6/17/2024	Buy	1,800	$9.81	$17,658.00	35,971
5/31/2024	Buy	2,500	$14.00	$35,000.00	34,171
12/18/2023	Buy	12,500	$2.60	$32,500.00	31,671

Jonathan Robert Hunt Buying and Selling Activity at Perspective Therapeutics

Perspective Therapeutics Company Overview

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Today's Range

Now: $2.39

$2.17

$2.41

50 Day Range

MA: $2.94

$2.05

$4.98

2 Week Range

Now: $2.39

$1.60

$5.39

Volume

1,930,567 shs

Average Volume

1,946,208 shs

Market Capitalization

$177.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Jonathan Hunt Biography and Net Worth

What is Jonathan Robert Hunt's net worth?

How old is Jonathan Robert Hunt?

What is Jonathan Robert Hunt's salary?

How do I contact Jonathan Robert Hunt?

Has Jonathan Robert Hunt been buying or selling shares of Perspective Therapeutics?

Who are Perspective Therapeutics' active insiders?

Are insiders buying or selling shares of Perspective Therapeutics?